Nrf2–Keap1 Pathway and NLRP3 Inflammasome in Parkinson’s Disease: Mechanistic Crosstalk and Therapeutic Implications
Open Access
- 20 November 2025
- journal article
- review article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 91
Abstract
Neurodegenerative disorders such as Parkinson’s disease (PD) are characterized by the progressive degeneration of dopaminergic neurons, which is driven primarily by oxidative stress and chronic neuroinflammation. Central to the cellular antioxidant defense system is the nuclear factor erythroid 2–related factor 2 (Nrf2)–Kelch-like ECH-associated protein 1 (Keap1) pathway, which mitigates oxidative damage and preserves mitochondrial integrity. Concurrently, the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome acts as a key mediator of innate immune responses and has been increasingly implicated in neuroinflammatory cascades leading to neuronal loss in PD. Emerging evidence indicates a mechanistic interplay between the Nrf2–Keap1 axis and the NLRP3 inflammasome, wherein Nrf2 activation not only counteracts oxidative stress but also suppresses NLRP3-mediated inflammatory signaling. A comprehensive overview of the molecular crosstalk between the Nrf2 and NLRP3 pathways in the pathogenesis of PD, with emphasis on how impaired Nrf2 signaling exacerbates NLRP3 inflammasome activation, is provided. The preclinical and clinical findings on pharmacological agents that activate Nrf2 or inhibit NLRP3 as potential neuroprotective strategies in PD are also discussed. A growing body of evidence underscores the dual therapeutic benefit of targeting oxidative stress and inflammation via Nrf2 inducers and NLRP3 inhibitors. Nonetheless, obstacles such as restricted blood–brain barrier permeability, unintended effects, and variable clinical trial outcomes hinder the application of these findings in clinical settings. The advancement of disease-modifying therapies for PD hinges on continuous research aimed at deepening the mechanistic understanding of the Nrf2–NLRP3 axis and refining pharmacological strategies.Keywords
This publication has 142 references indexed in Scilit:
- Emerging role of Nrf2 in Parkinson’s disease therapy: a critical reassessmentMetabolic Brain Disease, 2024
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)Clinical Pharmacology in Drug Development, 2022
- α‐Synuclein evokes NLRP3 inflammasome‐mediated IL‐1β secretion from primary human microgliaGlia, 2021
- Role of Microgliosis and NLRP3 Inflammasome in Parkinson’s Disease Pathogenesis and TherapyCellular and Molecular Neurobiology, 2021
- Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic CellsMolecular Neurobiology, 2020
- Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's diseaseMedicinal Research Reviews, 2020
- Neuroinflammation in the central nervous system: Symphony of glial cellsGlia, 2018
- ASC and NLRP3 impair host defense during lethal pneumonia caused by serotype 3 Streptococcus pneumoniae in miceEuropean Journal of Immunology, 2017
- Opposing effects of Nrf2 and Nrf2‐activating compounds on the NLRP3 inflammasome independent of Nrf2‐mediated gene expressionEuropean Journal of Immunology, 2017
- The cytoprotective role of the Keap1–Nrf2 pathwayArchives of Toxicology, 2011